Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (March 2024)
31 slides from Netramark's investor presentation, March 2024
Slide 1: Corporate Presentation March 2024
CSE: AIAI CORPORATE PRESENTATION OTCQB: AINMF March 2024 FRA: 8TV
Slide 2: Disclaimer
IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement presentation has been prepared by NetraMark Holdings Inc. (“NetraMark” or the “Company”) and conta
Slide 3: Risk Factors
RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those
Slide 4: Our Vision and Goals
The NetraMark vision is to have a material OUR VISION AND GOALS impact on the current 12% clinical trial success rate and serve the pharmaceutical industry’s demands for the efficient development of novel therapeutics and medicines CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 5: The Team
We have assembled a highly experienced leadership team OFFICERS George Achilleos Josh Spiegel Dr. Joseph Geraci Awards / Partnerships Chief Executive Officer President Chief Technology Officer / Chief Scientific Officer and Director George is a seasoned Business Executive with 25+ 25-plus years of e
Slide 6: The clinical trial market is robust, growing and large
The clinical trial market is robust, growing and large The number of cumulative clinical trials over time1 Number of interventional clinical studies, past 12 months1 450,000 399,522 400,000 2,500 362,500 350,000 325,771 293,254 2,000 300,000 262,299 250,000 233,124 1,500 205,335 2,300 200,000 181,22
Slide 7: Clinical Trials
Clinical Trials
Slide 8: Clinical trials are multi-phased projects that span many years
Clinical trials are multi-phased projects that span many years Drug Pre-Clinical Discovery THE CINICAL TRIAL From drug discovery through FDA approval, developing a new medicine takes, on average, 10 to 15 years and costs $2.6 billion USD.* Less than 12% of the candidate medicines that make it into P
Slide 9: Clinical trial related issues
Clinical trial related issues • Early phase trials not necessarily predictive of later phase CLINICAL TRIAL PROBLEMS & RISKS pivotal studies • Observed or potential adverse events can derail programs • Lack of separation in indications known for placebo response • Unexpected results for diseases wit
Slide 10: Is there a new approach to address clinical trial issues?
Is there a new approach to address clinical trial issues?
Slide 11: We must look in new places?
We must look in new places? Typical solutions are focused on improving Clinical Trial THE CINICAL TRIAL Operations / Implementation Source: https://www.cff.org/research-clinical-trials/how-do-clinical-trials-work
Slide 12: Could there be a way to have a direct impact on the protocol?
Could there be a way to have a direct impact on the protocol? Protocol THE CINICAL TRIAL A new protocol is developed at each phase of a clinical trial Source: https://www.cff.org/research-clinical-trials/how-do-clinical-trials-work
Slide 13: The Protocol
The Protocol Protocol Design Submit Protocol Approved to Regulator Protocol Begin Trial THE CINICAL TRIAL • Synopsis of the proposed trial • Therapeutic area • Objectives – primary and secondary • Study design • Population definition for the study • Inclusion criteria – who should be in the study •
Slide 14: The challenge of using AI to discover clinical trial protocol influential factors
The challenge of using AI to discover clinical trial protocol influential factors THE CHALLENGES The challenge centers around the ability to apply AI methods to small datasets and extract statistically significant insights that don’t overfit and can be utilized to enrich future studies
Slide 15: Over 95% of trials have less than 1,000 participants
Over 95% of trials have less than 1,000 participants Extracting statistically relevant findings from smaller population data sets to provide actionable insights for clinical trials is challenging. THE CHALLENGES Cumulative # of trials by anticipated # of participants (1999 – 2021)* 1-100 94,607 101-
Slide 16: Traditional methods provide a limited view of existing data
Traditional methods provide a limited view of existing data Unless there is a massive effect size in the data or a large sample size, traditional AG E S methods have limitations LAL ETN Traditional methods: T H E TCHHEAD • T-Tests and ANOVA • Chi-Square Test • Logistic Regression • Linear Regression
Slide 17: The NetraMark Solution – Attractor AI
The Attractor AI view of Genetic Non Small Cell Lung Cancer data The NetraMark solution - Attractor AI THE NETRAMARK SOLUTION – ATTRACTOR AI NetraAI will identify patients that require • Efficiently discovers which patients in a clinical trial can be explained different treatments, react differently
Slide 18: The NetraMark Solution: The Protocol
The NetraMark Solution The Protocol THE NETRAMARK SOLUTION We find statistically significant factors that could influence several parts of a protocol : • Population definition for the study • Inclusion criteria – who should be in the study • Exclusion criteria – who should not be in the study • Adve
Slide 19: Go To Market – Approach / Use Case / Pipeline
Go To Market – Approach / Use Case / Pipeline CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 20: The NetraMark Workflow
Step 1 The NetraMark Data preparation and ingestion Workflow Various data formats provided by the sponsor are prepared and ingested into a Sponsor specific instance of NetraAI Step 2 Step 3 Step 4 Step 5 THE WORKFLOW NetraAI NetraPlay AutoPlay Persona Tables NetraAI uses NetraPlay is an Augmented Au
Slide 21: Use Case – Schizophrenia Trial
Sponsor Brief: Phase IIa Schizophrenia Trial Project objectives Data included clinical scales: CGI-S, LOF, Strauss- • Characterize patient response to optimize USE CASE – SCHIZOPHRENIA TRIAL Carpenter Level of Functioning; mITT, PANSS, and in addition physiological measurements including heart rate,
Slide 22: Data Preparation and Ingestion
Data Preparation and Ingestion The process 1 • Data transferred to NetraMark via preferred Transcriptomics Sponsor compliant method HRENIA TRIAL Proteomics Genomics Clinical Trial Data • Specialized software is utilized to convert various types of data (e.g., transcriptomic, scales, imaging, Methyla
Slide 23: NetraMark AI Analysis: Placebo Response Hypothesis
NetraMark AI Analysis Placebo Response Hypothesis NetraAI HRENIA TRIAL The Attractor AI based NetraAI was able to identify subpopulations of patients consisting of nearly 50% of placebo responders that were highly explainable through a set of Placebo OTPA responders variables. ZA Placebo E ID non-re
Slide 24: NetraMark AI Analysis: Drug Response Hypothesis
NetraMark AI Analysis Drug Response Hypothesis NetraAI HRENIA TRIAL The Attractor AI based NetraAI was able to identify subpopulations of patients consisting of nearly 37.5 % of drug non-responders Drug that were highly explainable through a set of non-responders OTPA variables. ZA E ID These insigh
Slide 25: Using NetraAI to drive better results in late phase studies
Using NetraAI to drive better results in late phase studies By Combining NetraAI Hypotheses A Roadmap To Maximize Endpoint Effect Size is Generated USE CASE – SCHIZOPHRENIA TRIAL p = .04 • Assumption - a scaled-up version of the clinical trial consisting of 100 people in both the active and placebo
Slide 26: Use Case – Schizophrenia Trial
USE CASE – SCHIZOPHRENIA TRIAL
Slide 27: The Go To Market Approach
The Target Engagement Biotech or pharma company programs with clinical data in an indication of experience in these areas: • Oncology • Neurology THE GO TO MARKET APPROACH • Psychiatry • Metabolic • Rare & Orphan Disorders The Target Audience Leverage high level relationships & attend disease specif
Slide 28: The Business Model
Current Year Focus Current Results THE BUSINESS MODEL 65+ Leads in the sales pipeline Expanding the sales pipeline 30+ Channel partner discussions Leverage leadership pharmaceutical network Pharma Targeting outreach Aggressive conference schedule Build channel strategy Sales pipeline lead list build
Slide 29: The Pharmaceutical AI sector is producing high valuation multiples
The Pharmaceutical AI sector is producing high valuation multiples Comparison Estimated Revenue Pre-Money Valuation Valuation / Rev Multiple Owkin1 2020 ~ $12.15M Nov 2021 ~ $1.12B ~ 92X ConcertAI1 2022 ~ $53M Mar 2022 ~ $1.75B ~ 33X THE MARKET COMPS AITIA2 ~ $14M Jan 2020 ~ $120M ~ 8.6X PathAI3 ~ $
Slide 30: Thank you
Thank you For more information, please contact george@netramark.com CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 31: Statutory Rights of Action
STATUTORY RIGHTS OF ACTION In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy for rescission or damages, and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is or
NetraMark Holdings — Investor Presentation (March 2024) on 6ix